Nivolumab plus ipilimumab as a standard of care for unresectable MPM: 3-year CheckMate 743 update

ESMO-MCBS - A well-validated tool to assess clinical benefits of novel anti-cancer treatments in real-world practice

Population risk stratification in the early detection and personalized treatment for breast cancer

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent or metastatic cervical cancer: Phase 3 KEYNOTE-826 study

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab shows efficacy for early-stage TNBC: KEYNOTE-522 phase 3 trial

Durvalumab plus EP shows sustained OS benefit in ES-SCLC: 3-year update from phase 3 CASPIAN study